Ku蛋白质在急、慢性骨髓系白血病的表达及其意义

目的 本课题是研究在患有急性髓细胞白血病(acute myelocytic leukemia,AML)、急性淋巴细胞白血病(acute lymphoblastic leukemia, ALL)和慢性骨髓系白血病(chronic myelogenous leukemia, CML)患者中Ku蛋白的表达情况,为急慢性白血病的诊断和治疗提供有利临床应用价值。方法 选取2020年3月—2021年3月齐齐哈尔医学院附属第二医院收治的35例急性白血病患者周边血液与骨髓穿刺液,其中19例AML,16例ALL,另外,筛选BCR-ABL(+)CML的患者6例;对照组为12名正常人的周边血或骨髓穿刺液。在K562、HL-60、NB4细胞中转染Ku蛋白,利用实时定量PCR、流式细胞术鉴定Ku蛋白的基因表达;通过ELISA方法和Western blotting方法检测急慢性白血病中Ku蛋白的表达定位以及表达含量情况。应用米托司汀药物治疗前后对K562、HL-60、NB4细胞的增殖、凋亡、迁移、自噬等检测结果。结果 在所有急性白血病患者、AML、ALL的Ku70与Ku80表现,差异有统计学意义(P=0.001、0.036、0.046)。结论 延缓慢性白血病的发生、维护染色体结构完整性,防治染色体损伤而提供科学依据,为防治阻止DNA突变提供切实可行的分子诊断手段;同时对扩展急慢性白血病的放化疗治疗方案,制订个体化治疗措施具有重要意义。

Genotypic characteristics of resistant tumors to pre-operative ionizing radiation in rectal cancer

Due to a wide range of clinical response in patients un-dergoing neo-adjuvant chemoradiation for rectal cancer it is essential to understand molecular factors that lead to the broad response observed in patients receiving the same form of treatment.Despite extensive research in this field,the exact mechanisms still remain elusive.Data raging from DNA-repair to specific molecules lead-ing to cell survival as well as resistance to apoptosis have been investigated.Individually,or in combination,there is no single pathway that has become clinically applicable to date.In the following review,we describe the current status of various pathways that might lead to resistance to the therapeutic applications of ionizing radiation in rectal cancer.